Enanta Pharmaceuticals | ENTA - Trade Creditors


Enanta Pharmaceuticals reported $1.88M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Amgen USD 2.86B 16.65B Jun/2026
Anika Therapeutics USD 6.24M 103K Jun/2026
Arrowhead Research USD 27.78M 2.97M Jun/2026
AstraZeneca USD 22.89B 388M Jun/2026
BioCryst Pharmaceuticals USD 11.46M 501K Jun/2026
Biogen USD 403.9M 45.4M Jun/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 7M Jun/2026
Halozyme Therapeutics USD 23.61M 9.51M Jun/2026
Heron Therapeutics USD 11.64M 2.67M Jun/2026
Immunic USD 11.01M 873K Mar/2026
Incyte USD 1.39B 1.16B Jun/2026
Insmed USD 74.55M 1.18M Jun/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
J&J USD 9.22B 1.24B Jun/2026
Karyopharm Therapeutics USD 4.28M 276K Mar/2026
Ligand Pharmaceuticals USD 9.4M 27.7M Jun/2026
Merck USD 3.83B 36M Jun/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.26B 64M Jun/2026
Novavax USD 22.94M 6.84M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
Vertex Pharmaceuticals USD 3.61B 135M Jun/2026